R.A. Hiipakka et al. / Biochemical Pharmacology 63 72002) 1165±1176
1175
[5] Normington K, Russell DW. Tissue distribution and kinetic
characteristics of rat steroid 5a-reductase isozymes. Evidence for
distinct physiological functions. J Biol Chem 1992;267:19548±54.
[6] Levy MA, Brandt M, Sheedy KM, Holt DA, Heaslip JI, Trill JJ, Ryan
PJ, Morris RA, Garrison LM, Bergsma DJ. Cloning, expression and
functional characterization of type 1 and type 2 steroid 5a-reductases
from Cynomolgus monkey: comparisons with human and rat
isoenzymes. J Steroid Biochem Mol Biol 1995;52:307±19.
[7] Mahendroo MS, Russell DW. Male and female isoenzymes of steroid
5a-reductase. Rev Reprod 1999;4:179±83.
The effects of castration on advanced carcinoma of the prostate
gland. Arch Surg 1941;43:209±23.
[28] Liao S, Hiipakka RA. Selective inhibition of steroid 5a-reductase
isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate.
Biochem Biophys Res Commun 1995;214:833±8.
[29] Kao Y-H, Hiipakka RA, Liao S. Modulation of endocrine systems
and food intake by green tea epigallocatechin gallate. Endocrinology
2000;141:980±7.
[30] Liang T, Liao S. Inhibition of steroid 5a-reductase by specific
aliphatic unsaturated fatty acids. Biochem J 1992;285:557±62.
[31] Lesuisse D, Berjonneau J, Ciot C, Devaux P, Doucet B, Gourvest JF,
Khemis B, Lang C, Legrand R, Lowinski M, Maquin P, Parent A,
Schoot B, Teutsch G. Determination of oenothein B as the active 5a-
reductase inhibiting principle of the folk medicine Epilobium
parviflorum. J Nat Prod 1996;59:490±2.
[8] Thigpen AE, Cala KM, Russell DW. Characterization of Chinese
hamster ovary cell lines expressing human steroid 5a-reductase
isozymes. J Biol Chem 1993;268:17404±12.
[9] Mahendroo MS, Porter A, Russell DW, Word RA. The parturition
defect in steroid 5a-reductase type 1 knockout mice is due to
impaired cervical ripening. Mol Endocrinol 1999;13:981±92.
[10] Mahendroo MS, Cala KM, Russell DW. 5a-Reduced androgens play
a key role in murine parturition. Mol Endocrinol 1996;10:380±92.
[11] Mahendroo MS, Cala KM, Landrum CP, Russell DW. Fetal death in
mice lacking 5a-reductase type 1 caused by estrogen excess. Mol
Endocrinol 1997;11:917±27.
[32] Ducrey B, Marston A, Gohring S, Hartman RW, Hostettmann K.
Inhibition of 5a-reductase and aromatase by the ellagitannins
oenothein A and oenothein B from Epilobium species. Planta Med
1997;63:111±4.
[33] Evans BAJ, Griffiths K, Morton MS. Inhibition of 5a-reductase in
genital fibroblasts and prostate tissue by dietary lignans and
isoflavanoids. J Endocrinol 1995;147:295±302.
[12] Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid
5a-reductase deficiency in man: an inherited form of male
pseudohermaphroditism. Science 1974;186:1213±5.
[34] Ishiguro K, Oku H, Kato T. Testosterone 5a-reductase inhibitor
bisnapthoquinone derivative from Impatiens balsamina. Phytother
Res 2000;14:54±6.
[13] Wilson JD, Griffin JE, Russell DW. Steroid 5a-reductase
deficiency. Endocr Rev 1993;14:577±93.
2
[35] Shimizu K, Fukuda M, Kondo R, Sakai K. The 5a-reductase
inhibitory components from heartwood of Artocarpus incisus:
structure±activity investigations. Planta Med 2000;66:16±9.
[36] Grunberger D, Banerjee R, Eisinger K, Oltz EM, Efros EM, Caldwell
M, Estevez V, Nakanishi K. Preferential cytotoxicity on tumor cells
by caffeic acid phenethyl ester from propolis. Experientia
1988;44:230±2.
[14] Horton R. Benign prostatic hyperplasia: new insights.
Endocrinol Metab 1992;74:504A±C.
J Clin
[15] Sansone G, Reisner RM. Differential rates of conversion of
testosterone to dihydrotestosterone in acne and in normal human
skin: a possible pathogenic factor in acne. J Invest Dermatol
1971;56:366±72.
[16] Bingham KD, Shaw DA. The metabolism of testosterone by human
male scalp skin. J Endocrinol 1973;25:83±91.
[37] Plattner JJ, Gless RD, Rapoport H. Synthesis of some DE and CDE
ring analogs of camptothecin. J Am Chem Soc 1972;94:8613±5.
[17] Schweiker HU, Wilson JD. Regulation of human growth by steroid
hormones. I. Testosterone metabolism in isolated hairs. J Clin
Endocrinol Metab 1974;38:811±9.
[38] Meth-Cohn O. A simple, powerful and efficient method for
transesterification. J Chem Soc, Chem Commun 1986;1986:695±7.
[39] Nystrom JE, McCanna TD, Helquist P, Iyer RS. Short intramolecular
Diels±Adler approach to functionalized spiro[4.5]decances. Tetra-
hedron Lett 1985;26:5393±6.
[18] Kuttenn F, Mowszowicz I, Schaison G, Mauvais-Jarvis P. Androgen
production and skin metabolism in hirsutism.
1977;25:83±91.
J Endocrinol
[40] Kirschmeier PT, Housey GM, Johnson MD, Perkins AS, Weinstein
[19] Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC,
Henderson BE. 5a-Reductase activity and risk of prostate cancer
among Japanese and US white and black males. Lancet
1992;339:887±9.
IB. Construction and characterization of a retroviral vector
demonstrating efficient expression of cloned cDNA sequences.
DNA 1988;7:219±25.
[41] Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer
helper-free retroviruses by transient transfection. Proc Natl Acad Sci
USA 1993;90:8392±6.
[20] Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel
LN, Shi C-Y, Yu MC, Henderson BE, Reichardt JKV. A prevalent
missense substitution that modulates activity of prostatic steroid 5a-
reductase. Cancer Res 1997;57:1020±2.
[42] Felsher DW, Bishop JM. Transient excess of MYC activity can elicit
genomic instability and tumorigenesis. Proc Natl Acad Sci USA
1999;96:3940±4.
[21] Stoner E. The Finasteride Study Group. The clinical effects of a 5a-
reductase inhibitor, finasteride, on benign prostatic hyperplasia. J
Urol 1992;147:1298±302.
[43] Topp WC. Normal rat cell lines deficient in nuclear thymidine kinase.
Virology 1981;113:408±11.
[22] Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld
W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J,
Binkowitz B, Gormley GJ. The Finasteride Male Pattern Hair Loss
Study Group. Finasteride in the treatment of men with androgenetic
alopecia. J Am Acad Dermatol 1998;39:578±89.
[44] Brown AMC, Scott MRD, Retroviral vectors. In: Glover DM, editor.
DNA cloning, a practical approach, vol. III. Oxford: IRL Press, 1987.
p. 189±212.
[45] Zhu Q-Y, Zhang A, Tsang D, Huang Y, Chen ZY. Stability of green
tea catechins. J Agric Food Chem 1997;45:4624±8.
[46] Zimeri J, Tong CH. Degradation kinetics of ,À)-epigallocatechin
gallate as a function of pH and dissolved oxygen in a liquid model
system. J Food Sci 1999;64:753±8.
[23] Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS. 5a-
Reductase inhibition and prostate cancer prevention. Cancer
Epidemiol Biomarkers Prev 1994;3:177±82.
[24] Kolonel LN, Nomura AMY, Cooney RV. Dietary fat and prostate
cancer: current status. J Nat Cancer Inst 1999;91:414±28.
[25] Clinton SK, Giovannucci E. Diet, nutrition and prostate cancer. Ann
Rev Nutr 1998;18:413±40.
[47] Miura YH, Tomita I, Watanabe T, Hirayama T, Fukui S. Active
oxygens generation by flavanoids. Biol Pharm Bull 1998;21:93±6.
[48] Long LH, Clement MV, Halliwell B. Artifacts in cell culture: rapid
generation of hydrogen peroxide on addition of ,À)-epigallocatechin,
,À)-epigallocatechin gallate, ,)-catechin, and quercitin to com-
monly used cell culture media. Biochem Biophys Res Commun
2000;273:50±3.
[26] Huggins C, Hodges CV. Studies of prostatic cancer. I. The effect of
castration. Cancer Res 1941;1:293±7.
[27] Huggins C, Stevens RE, Hodges CV. Studies of prostatic cancer. II.